39.9 F
New York
Wednesday, November 30, 2022

Date:

Share:

Vesalio Initiates FDA IDE Stroke Study

Related Articles

Nashville, TN, May 11, 2021 –(PR.com)– Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVa(TM) thrombectomy technology platform. With twenty participating stroke treatment centers, enrollment is expected to be completed in early 2022.

Ischemic stroke is caused when a blood clot blocks an artery in the brain causing an area of the brain to die. It is one of the leading causes of death and long-term disability globally. In the U.S. 800,000 patients are estimated to suffer from a stroke each year. Although the risk increases with age, a stroke can occur at any age.

“There have been over 3,200 stroke patients treated with the NeVa thrombectomy platform in Europe and other global markets. The recanalization results have been impressive with high first-pass efficacy across…

Read more…

Popular Articles